HDAC inhibitors, DNA alkylators and nucleoside analogs are effective components of combination chemotherapy.
2
On the other hand, the use of alkylators and topoisomerase II inhibitors is associated with an increased risk of t-AML.
3
The protein level of MRP1 correlated with cellular resistance to busulfan and chlorambucil, and Rom exposure sensitized cells to these DNA alkylators.
4
To determine a possible mechanism of their synergism, we analyzed the effects of HDAC inhibitors on the expression of drug transporters which export DNA alkylators.